Alcresta Therapeutics Announces Preclinical Data Evaluating RELiZORBneo Cartridge Use in Neonatal Murine Model of Necrotizing Enterocolitis

Preclinical data published in PLOS ONE highlight potential safety benefit of RELiZORBneo WALTHAM, Mass., May 1, 2026 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced...